Chapter 11 - THE SAFETY COMMITTEE
The confrontation with Carter Biomedical’s safety committee took place under outside legal supervision. Evelyn attended as a family representative and potential witness. Daniel joined remotely because Lily had a school appointment that morning, and neither parent wanted her schedule rearranged around another corporate crisis.
The committee reviewed the original drug administration record, Lily’s laboratory results, the known risk memorandum, and the subsequent safety classification. A physician explained that the reaction was consistent with a recognized complication and should have been reported as a serious suspected adverse drug event.
The company’s current classification described it as an unrelated cardiac episode.
The alteration occurred six days after Lily’s hospitalization.
Approving official:
Dr. Samuel Voss.
Executive review:
Arthur Carter.
Arthur’s attorney argued that causation remained uncertain and the original clinical judgment could have been reasonable under the circumstances. That was a legitimate scientific question. It did not explain why the report omitted the drug administration entirely.
The committee separated the issues.
Whether the drug caused every symptom required expert assessment.
Whether Lily received it without valid documented consent was a different question.
Whether the company concealed the exposure was different again.
Arthur had spent six years blending those questions because uncertainty about causation made everything else sound uncertain too.
The committee refused to continue using the old classification.
That decision triggered mandatory internal escalation and notification to appropriate authorities. The acquisition team suspended closing preparations pending an independent safety investigation.
Arthur’s financial interests were now directly threatened.
Then Voss offered to cooperate.
His attorney explained that Voss had been under pressure from Arthur’s legal team for years. He agreed to alter the adverse-event narrative after receiving assurances the family had resolved the consent problem privately.
Voss admitted he knew those assurances were incomplete.
He feared losing research funding, hospital privileges, and professional standing if the original treatment decision became public.
The confession supported the concealment but also exposed Voss’s own choices.
No one had forced him to falsify the report at gunpoint.
He selected professional survival over an accurate record.
The complication came when Voss produced an email from Daniel.
Three days before Lily’s treatment, Daniel asked about experimental options and said he was willing to “consider anything that could help.”
Arthur’s attorney presented it as evidence of implied consent.
Evelyn felt a familiar flash of anger at Daniel.
He had not told her about that email.
Daniel admitted writing it.
“I was frightened. I wanted information.”
“Did you agree to the drug?”
“No.”
The email did not establish valid consent.
But it showed Daniel had been more involved in the discussion than his public narrative suggested.
After the hearing, Evelyn confronted him privately.
“I can fight my father without pretending you were perfect.”
Daniel looked exhausted.
“I know.”
“You need to stop giving me the version that makes you easiest to defend.”
He nodded.
That was the first time she believed their cooperation might survive the truth.
Then Detective Brooks called.
Malcolm Redd had attempted to access Lily’s school pickup records using a forged authorization from Carter Family Office.
He was stopped.
His lawyer claimed an administrative misunderstanding.
Brooks disagreed.
May you like
The case had moved beyond surveillance.
Someone was preparing to exercise physical control over Lily again.
